- $5.52bn
- $6.47bn
- $1.33bn
Haemonetics Corp reports results for the quarter ended March 31 - Earnings Summary
Brief: Haemonetics Corp Qtrly Revenue $331 Million
Brief: Haemonetics Announces Executive Leadership Updates
U.S. STOCKS ON THE MOVE-Super Micro Computer, WEX, MarketAxess
Haemonetics hits two-year low after cutting sales growth forecast
Haemonetics Corp reports results for the quarter ended December 31 - Earnings Summary
Brief: Haemonetics Corp Reports Q3 Revenue Of $348.5 Million, Up 3.7% YoY
Brief: Haemonetics Completes Sale Of Whole Blood Assets To Gvs, S.P.A
U.S. RESEARCH ROUNDUP- Doordash, Sagimet Biosciences, Ulta Beauty
Brief: Haemonetics Announces Sale Of Whole Blood Assets To Gvs for Up To $67.1 Mln
Haemonetics Corp reports results for the quarter ended in September 30 - Earnings Summary
Brief: Haemonetics Corp Qtrly Revenue $346 Million
Brief: Haemonetics Corp Reaffirms Fiscal 2025 EPS Outlook
Brief: Aligos Therapeutics Strengthens Senior Leadership Team With The Appointment Of Hardean Achneck, MD As Chief Medical Officer
Haemonetics Corp expected to post earnings of $1.01 a share - Earnings Preview
Brief: Sotera Health Appoints Christopher Simon To The Board Of Directors
Brief: Haemonetics Announces CE Mark Certification For The Savvywire® Pre-Shaped Pressure Guidewire
Brief: Haemonetics Launches Limited Market Release For New Vascade Mvp Xl Vascular Closure Device
Brief: Haemonetics Announces Proposed Convertible Senior Notes Offering